Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

    96 Citationer (Scopus)

    Abstract

    The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.
    OriginalsprogEngelsk
    TidsskriftExpert Opinion on Investigational Drugs
    Vol/bind16
    Udgave nummer2
    Sider (fra-til)231-7
    Antal sider7
    ISSN1354-3784
    DOI
    StatusUdgivet - 1 feb. 2007

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus'. Sammen danner de et unikt fingeraftryk.

    Citationsformater